Octapharma Italy S.p.A. was established in Pisa on July 8th 2008. Previously, Octapharma Group distributed its products through third companies, and since the beginning the decision was made to start off with a streamlined structure covering only the essential functions able to guarantee the company’s start-up, outsourcing all other staff functions.
The current structure is composed of the following functions: the Managing Director and his Staff, Regulatory Affairs Compliance & Logistics, Tender Office, Customer Care, Administration & Finance, and Key Accounts.
The core business, according to the whole Octapharma Group, are: medical liaison, registration, clinical research and marketing of human proteins for therapeutic use in the following areas: Haematology, Immunotherapy, Intensive care and Urgency medicine. In a market like the Italian one, distinguished as it is by the absolute prevalence of regional tenders, and characterized by the strong presence of a Self Sufficiency Program (SSP), the main activities of Octapharma Italy S.p.A. are participation in tenders, customer care, the development of projects on the territory including participation in the more relevant congresses, efficient and where possible innovative logistics, together with product availability.
In 2015 Octapharma Italy S.p.A. was accredited to bid for the tenders issued in the framework of the Self Sufficiency Program and this could open interesting future perspectives for the company.
Contact
Address: Via Cisanello, 145, 56124 Pisa PI, Italy
Phone:+39 050 549001
Octapharm’s Abramo Brandi, Managing Director of Italy and VP Africa, outlines the particularities of the plasma derivatives business in general and the Italian market in particular. He also explains the…
Abramo Brandi, Octapharma Italy’s MD, discusses the challenges of the tender system in Italy and how he has grown the company year-on-year in the midst of a global economic crisis.…
A roundup of some of the biggest stories from Italian pharma and healthcare, including Italfarmaco’s FDA approval for its DMD treatment; Alfasigma’s acquisition of Galapagos’s Jyseleca, the antibiotics deal between…
The grants and loans allocated by the European Union’s Recovery and Resilience Facility (RRF), a large part of which have been assigned to healthcare, set out to mitigate the economic…
After former CEO Pierluigi Antonelli abruptly announced his departure last month, the Italian mid-cap has signed on former Gilead leader, Jacopo Andreose, as its new chief executive. [I am]…
Angelini Pharma CEO Pierluigi Antonelli has announced that he is leaving his position with immediate effect, posing the question of what comes next for the leading Italian mid-cap. Antonelli,…
The electoral victory of the centre-right coalition in Italy should see far-right firebrand Giorgia Meloni replace former European Central Bank President Mario Draghi as Prime Minister at the end of…
Digitalisation has become a buzz word in in the global life sciences sector. In Italy, digital transformation has taken on special significance as one of the principal goals encompassed in…
The Italian system requires drug companies to go through approvals at a national level with the Italian Medicines Agency (AIFA), only to then confront the country’s 21 regional authorities who…
Historically, SIFI has been a modest local player focused on ophthalmic products, but in recent years the company has set some ambitious goals for itself—becoming a leading force in European…
Seasoned executive Pierluigi Antonelli went from a career in big pharma to Angelini Pharma, a midsized Italian company that has been undergoing major transformation. He shares the motivation behind the…
Collectively representing almost 400 companies operating in Italy, Farmindustria, Egualia (formerly Assogenerici) and Assobiotec respectively promote the interests of innovative pharmaceutical companies—both foreign and Italian-owned— the generics, biosimilars and value-added…
As the European Union’s largest beneficiary of the Next Generation EU (NGEU) package, aimed at boosting the EU’s economy following the COVID-19 pandemic, Italy will receive some EUR 235 billion…
While Italy’s biotech landscape is generally held to be somewhat immature in comparison to more established markets such as Germany, France or the UK, that does not imply a deficit…
See our Cookie Privacy Policy Here
